(Q38389823)

English

Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

scientific article published on July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease (English)

1 reference

Europe PubMed Central

2 September 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

André J Scheen

1

1 reference

Europe PubMed Central

2 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 July 2015

1 reference

Europe PubMed Central

2 September 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

2 September 2017

54

1 reference

Europe PubMed Central

2 September 2017

7

1 reference

Europe PubMed Central

2 September 2017

691-708

1 reference

Europe PubMed Central

2 September 2017

https://scigraph.springernature.com/pub.10.1007/s40262-015-0264-4

0 references

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Management of type 2 diabetes: new and future developments in treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

SGLT inhibitors in management of diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

SGLT2 inhibitors in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Renal glucose reabsorption inhibitors to treat diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Dapagliflozin: a review of its use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Dapagliflozin: a review of its use in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Canagliflozin: first global approval

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Canagliflozin: a review of its use in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Ipragliflozin: first global approval

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Tofogliflozin: first global approval

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

SGLT2 inhibitors: their potential reduction in blood pressure

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Renal effects of dapagliflozin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

Luseogliflozin: First Global Approval

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0264-4

21 January 2018

A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/25805666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25805666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin: a review of its use in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25805666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25805666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-015-0264-4

1 reference

Europe PubMed Central

2 September 2017

Dimensions Publication ID

0 references

release_ipbtx2kv3rbo7pbo4njmg24gzq

1 reference

https://api.fatcat.wiki/v0/release/ipbtx2kv3rbo7pbo4njmg24gzq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38389823&oldid=2143924463"